Skip to main content

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients

Medical Oncology volume 28, pages 605–612 (2011)Cite this article

Abstract

The proven benefit of third-line treatment in advanced non-small cell lung cancer (NSCLC) is still unclear. We retrospectively evaluated the outcome of advanced NSCLC patients treated with third-line therapies in our institution, especially focusing on efficacy and toxicity between mono-therapy and doublets chemotherapy, aiming to assess the value of third-line treatment and evaluate the efficacy of different regimens in third-line treatment. Three hundred and seventeen patients received a second-line treatment among 620 advanced NSCLC after failure of first-line chemotherapy. One hundred and twenty-six patients from this group were offered third-line or further-line treatments. Survival analysis was conducted based on Kaplan–Meier method, and Chi-square was used to compare data between second-line and third-line group. There were significant differences in overall survival between second-line and third-line treatments (17.70 months vs. 24.03 months, P < 0.0001). Twenty-four patients received single chemotherapy, epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) were used to treat thirty-three patients and sixty-nine patients received doublet chemotherapy in third-line treatment. The progression-free survival (PFS) after third-line therapy was 2.37 months in all patients and 2.30 months, 2.80 months, 2.97 months, in the doublet chemotherapy, single-agent chemotherapy, and EGFR-TKIs arms, respectively (P = 0.033). Cancer-related symptom relief improvement was confirmed in 78.9% patients (60/78). Forty-eight patients had no symptoms as confirmed by imaging examination. Patients with advanced NSCLC could get benefits from third-line treatments. Those patients could obtain a moderate progression-free survival and conspicuous improvement in the cancer-related symptom. Mono-therapy was recommended in third-line treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Jemal A, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–49.

    PubMed  Article  Google Scholar 

  2. Pass H, et al. Lung cancer: principles and practice. Philadelphia: Lipponcott Williams & Wilkins; 2000.

    Google Scholar 

  3. Petrelli NJ, et al. Clinical cancer advances 2009:major research advances in cancer treatment, prevention, and screening-A reports from the american society of clinical oncology. J Clin Oncol. 2009;27:6052–69.

    PubMed  Article  Google Scholar 

  4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J. 1995;311:899–909.

    Article  Google Scholar 

  5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized clinical trials. J Clin Oncol. 2008;26:4617–25.

    Article  Google Scholar 

  6. Schiller JH, et al. Eastern cooperative oncology group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.

    PubMed  Article  CAS  Google Scholar 

  7. Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.

    PubMed  CAS  Google Scholar 

  8. Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–62.

    PubMed  CAS  Google Scholar 

  9. Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.

    PubMed  Article  CAS  Google Scholar 

  10. Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.

    PubMed  Article  CAS  Google Scholar 

  11. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.

    PubMed  Article  CAS  Google Scholar 

  12. Sun JM, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol. 2008;39:27–32.

    PubMed  Article  Google Scholar 

  13. Nicolas G, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009;4:1544–9.

    Article  Google Scholar 

  14. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    PubMed  Article  CAS  Google Scholar 

  15. Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181.

    Google Scholar 

  16. Christopher GA, et al. American society of clinical oncology clinical practice. Guideline update on chemotherapy for stage IV non–small-cell lung cancer. J Clin Oncol. 2009;27:6251–66.

    Article  Google Scholar 

  17. Yoshino I, et al. A time trend of profile and surgical results in 1123 patients with non-small cell lung cancer. Surgery. 2002;131:S242–8.

    PubMed  Article  Google Scholar 

  18. Massarelli E, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer. 2003;39:55–61.

    PubMed  Article  CAS  Google Scholar 

  19. Maio MD, et al. Meta-Analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non–small-cell lung cancer. J Clin Oncol. 2009;27:1836–43.

    PubMed  Article  Google Scholar 

  20. Kim HS, et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 2010;70:71–6.

    PubMed  Article  Google Scholar 

  21. Smit EF, et al. A radomized phase II Study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC)-NVALT7. J Clin Oncol. 2008; 26:436 s, (abstract 8050).

    Google Scholar 

  22. Chen YM, et al. Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy. J Thorac Oncol. 2006;1:545–50.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Shanghai Lung Tumor Clinical Medical Center, Chest Hospital Affiliated to Shanghai Jiaotong University, 241 West Huaihai Road, Xuhui District, 200030, Shanghai, China

    Zhengbo Song, Yongfeng Yu, Zhiwei Chen & Shun Lu

Authors
  1. Zhengbo Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongfeng Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiwei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shun Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shun Lu.

Additional information

Zhengbo Song, Yongfeng Yu, Zhiwei Chen have contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Song, Z., Yu, Y., Chen, Z. et al. Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients. Med Oncol 28, 605–612 (2011). https://doi.org/10.1007/s12032-010-9753-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9753-3

Keywords

  • Non-small cell lung cancer
  • Third-line treatment
  • Progression-free survival
  • Overall survival